Trial Status

Cancer Type

NeuroEndocrine Tumours (NETs)

If you think this trial is relevant to your situation, please contact your Cancer Specialist to discuss further.

Protocol Title

CONTROL NETs translational sub-study

Purpose of the Study

Peptide Receptor Radionuclide Therapy (PRRT) is an effective treatment for neuroendocrine tumours (NETs). CONTROL NETs, an AGITG study in follow up, tested whether adding chemotherapy to PRRT will make it more effective, the results are currently demonstrating an encouraging increase in tumour shrinkage. Normally we know who can benefit from PRRT, because their NET tumours will light up on a special type of PET scan (Gallium68 PET). However, we don’t have a way of knowing which patients will benefit from adding chemotherapy to the PRRT. The most likely way of finding who will benefit from chemotherapy is testing for a gene called MGMT.

This substudy of the CONTROL NETs trial will investigate whether testing MGMT in several ways at the same time (‘multi-omic testing’), and combining the results of these tests, can predict who will benefit from adding chemotherapy to PRRT. If it works, we will be able to identify who needs to have chemotherapy with PRRT, and who can have PRRT on its own.

Contact Email



More detailed information to come.

Principal Investigator

Dr Ben Lawrence


2020 Innovation Grant

Trial Status

Cancer Type

NeuroEndocrine Tumours (NETs)

If you think this clinical trial may be relevant to your patient or to discuss further, please contact the Clinical Trial team.